21,532 Shares in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Acquired by SteelPeak Wealth LLC

SteelPeak Wealth LLC purchased a new stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 21,532 shares of the company’s stock, valued at approximately $161,000.

Other hedge funds have also recently made changes to their positions in the company. Mubadala Investment Co PJSC purchased a new position in Recursion Pharmaceuticals during the fourth quarter worth about $128,041,000. Gladstone Institutional Advisory LLC purchased a new position in shares of Recursion Pharmaceuticals during the fourth quarter worth about $133,000. Capstone Investment Advisors LLC bought a new position in shares of Recursion Pharmaceuticals in the first quarter worth approximately $161,000. Norges Bank purchased a new stake in Recursion Pharmaceuticals in the fourth quarter valued at approximately $34,825,000. Finally, Sumitomo Mitsui Trust Holdings Inc. lifted its position in Recursion Pharmaceuticals by 161.2% during the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 9,203,780 shares of the company’s stock valued at $90,749,000 after purchasing an additional 5,680,656 shares during the last quarter. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Recursion Pharmaceuticals news, CFO Michael Secora sold 15,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $6.35, for a total value of $95,250.00. Following the transaction, the chief financial officer now directly owns 1,340,968 shares of the company’s stock, valued at approximately $8,515,146.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Recursion Pharmaceuticals news, CFO Michael Secora sold 15,000 shares of the stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $6.35, for a total transaction of $95,250.00. Following the completion of the sale, the chief financial officer now owns 1,340,968 shares of the company’s stock, valued at approximately $8,515,146.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Christopher Gibson sold 50,000 shares of the firm’s stock in a transaction on Wednesday, June 5th. The stock was sold at an average price of $8.42, for a total transaction of $421,000.00. Following the completion of the sale, the chief executive officer now directly owns 758,738 shares in the company, valued at approximately $6,388,573.96. The disclosure for this sale can be found here. In the last quarter, insiders sold 258,682 shares of company stock valued at $2,040,718. Insiders own 15.75% of the company’s stock.

Recursion Pharmaceuticals Trading Up 6.5 %

Shares of RXRX stock traded up $0.41 during trading hours on Thursday, hitting $6.69. 4,986,472 shares of the company’s stock were exchanged, compared to its average volume of 6,052,134. Recursion Pharmaceuticals, Inc. has a 12-month low of $4.97 and a 12-month high of $15.74. The company has a market capitalization of $1.59 billion, a PE ratio of -4.18 and a beta of 0.83. The business’s 50 day simple moving average is $7.97 and its 200-day simple moving average is $9.24.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its earnings results on Thursday, August 8th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative return on equity of 86.35% and a negative net margin of 755.37%. The business had revenue of $14.42 million during the quarter, compared to analysts’ expectations of $11.96 million. During the same quarter in the previous year, the business earned ($0.38) EPS. Recursion Pharmaceuticals’s revenue for the quarter was up 30.9% compared to the same quarter last year. Equities analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.56 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have recently commented on RXRX shares. Needham & Company LLC decreased their price target on shares of Recursion Pharmaceuticals from $17.00 to $16.00 and set a “buy” rating on the stock in a report on Friday, August 9th. KeyCorp dropped their price target on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating for the company in a research note on Thursday, July 11th.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.